A Phase 1b Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of TAK-079 in Combination With Standard Background Therapy in Patients With Moderate to Severe Systemic Lupus Erythematosus
Phase of Trial: Phase I
Latest Information Update: 11 Nov 2019
Price : $35 *
At a glance
- Drugs TAK 079 (Primary)
- Indications Systemic lupus erythematosus
- Focus Adverse reactions
- Sponsors Takeda Oncology
- 01 Mar 2019 According to a Lupus Therapeutics media release, the company alongwith its affiliate The Lupus Research Alliance entered into a collaboration with Takeda Pharmaceutical Company for this trial. The study will be conducted in 20 research centers throughout the U.S., many of which are members of Lupus Therapeutics' Lupus Clinical Investigators Network (LuCIN).
- 06 Dec 2018 Status changed from not yet recruiting to recruiting.
- 02 Nov 2018 New trial record